More stringently, in other words.
Researchers at UCSF argue that the cannabis industry should be regulated more like tobacco than alcohol, for public health reasons. Sales should be “subject to a robust demand reduction program modeled on successful evidence-based tobacco control programs,” they write.
REC sales are now treated more like alcohol, which the researchers consider more loosely controlled and easier to exploit. For example, alcohol advertising is much more widely permitted than tobacco advertising.
Through the Freedom of Information Act, attn: reveals FDA’s thought’s on rescheduling marijuana, before the DEA decided not to. If I’m reading correctly, FDA seems skeptical of both the current system and DEA’s ability to reform it.
A study found that smoking pot can increase the risk of psychosis relapse.
A bipartisan group of nine U.S. Senators has asked the DEA not to add kratom to the list of schedule I drugs. Signers included both Republican Senators from Utah, a nutraceutical industry hub. Vox explains the kratom situation here.
The University of New Mexico is establishing a MED research fund.
FuturePAC, which supports Democrats in the Oregon House of Representatives, held a fundraiser at a grow.
Chelsea Clinton suggested that marijuana could cause fatal interactions with other drugs and then retracted the statement.
A ballot initiative Tuesday in Alaska could ban REC businesses in the Matanuska-Susitna Borough, which is both a population center and Alaska’s most celebrated growing region. MED is on the march in Idaho, which Boise-native Russ Belville says will be the last state to legalize.
After decades of gray market cannabis, the Netherlands could legalize growing.